<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00218426</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-17317-1</org_study_id>
    <secondary_id>R01DA017317</secondary_id>
    <secondary_id>R01-17317-1</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00218426</nct_id>
  </id_info>
  <brief_title>Addiction Treatment in Russia: Oral vs. Naltrexone Implant</brief_title>
  <official_title>Addiction Treatment in Russia: Oral and Depot Naltrexone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heroin addiction is a growing problem in Russia; individuals who enter heroin addiction
      treatment often relapse. Therefore, effective heroin addiction treatments are necessary to
      prevent relapse. The purpose of this study is to compare oral naltrexone with a naltrexone
      implant that provides opioid blockade for two months in preventing relapse to heroin
      addiction in St. Petersburg, Russia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The usual treatment of heroin addiction in Russia involves detoxification and 2-4 weeks of
      rehabilitation with referral to outpatient follow-up. Though most patients complete inpatient
      treatment, few keep follow-up appointments and relapse rates are high. More effective
      therapies are needed, especially in view of the epidemic of heroin addiction that has
      resulted in the spread of HIV and other infectious diseases. A recently-completed study of 52
      patients randomized to oral naltrexone (ON) or oral naltrexone placebo (ONP) has shown
      efficacy in preventing relapse and reducing HIV risk but dropout was a problem with only 44%
      of ON patients proven to have not relapsed by 6 months (as compared to 16% of ONP patients).
      A larger study of 280 patients randomized to ON or ONP replicated these results and found
      some indication that adding an selective serotonin reuptake inhibitor (SSRI) to naltrexone
      may improve its efficacy in women, probably because they tend to have higher levels of
      psychiatric symptoms than men.

      We think that retention and outcome can be improved by using a longer acting naltrexone
      preparation, and in this study we propose to compare ON with a depot naltrexone implant (DNI)
      that is manufactured and approved for use in Russia, and provides opioid blockade for 8-10
      weeks. We will use a placebo-controlled, double-blind/double-dummy design since a
      placebo-controlled trial is required by the Russian equivalent of our FDA as a condition for
      testing a pharmacotherapy. Participants will be male and female heroin addicts who have been
      detoxified in addiction treatment hospitals or outpatient settings in St. Petersburg and have
      a family member willing and able to supervise medication adherence and facilitate follow-up.
      After giving informed consent and confirming the absence of physiologic dependence, 306
      patients will be randomly assigned to a 6-month treatment in one of three groups of 102 each:
      oral naltrexone (ON) + depot naltrexone implant placebo (DNIP); oral naltrexone placebo (ONP)
      + depot naltrexone implant (DNI); or ONP + DNIP. All patients will receive biweekly clinical
      management/adherence enhancement counseling. Assessments will be done at baseline, at each
      biweekly appointment during the 6-months of medication treatment, and at 3 and 6 months
      following the end of study medication. Primary outcome will be the relapse free proportion at
      months 1-6; secondary outcomes will be time to dropout, opioid positive urines, HIV risk, use
      of alcohol and other drugs, psychiatric symptoms, and other measures of overall adjustment.
      We hypothesize that outcomes will be better with DNI than ON, and that each will be more
      effective than placebo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2006</start_date>
  <completion_date type="Actual">November 4, 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Retention Without Relapse to Heroin Addiction (Measured at Month 6)</measure>
    <time_frame>6 months</time_frame>
    <description>Survival analysis (Kaplan-Meier survival functions with log-rank Cox-Mantel criteria for group comparison was used to determine the primary outcome of retention, defined as not missing 2 consecutive counseling sessions and not having a relapse. Because this outcome combined patients who failed to keep appointments with those who kept appointments but relapsed, the proportion of non-survivors attributable to proven relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Dropped Out of Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Kaplan-Meier survival curves for the event of subjects who dropped out of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive Opioid Urine Test</measure>
    <time_frame>6 months</time_frame>
    <description>missed urine tests were imputed to be positive for opiates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Alcohol</measure>
    <time_frame>6 months</time_frame>
    <description>use of alcohol grams per day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Score of Psychiatric Problems</measure>
    <time_frame>6 months</time_frame>
    <description>composite score is a decimal score; with 0 = no problems, 1 = the most problems based on the Addiction Severity Index composite score of 11 indexed questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV Risk (Baseline)</measure>
    <time_frame>baseline</time_frame>
    <description>The Risk Assessment Behavior (RAB), is an HIV risk Scale. The Total Score is scored by adding the values that correspond to the responses selected by the subject for the items asked. This highest total score is 40 (highest risk), and the lowest score = 0 (no risk). This assessment has 2 Subsections: 1) Drug Risk = 8 questions (lowest Drug Risk score = 0 (no risk), and highest drug risk score = 22 =(greatest risk), 2) 10 Sex Risk questions: scores are 0 = no risk, and 18 = highest risk). Total RAB Score = Drug Risk Total + Sex Risk Total (0 = no risk, 40 = highest). See: Risk Assessment Battery (RAB) Scoring System, https://www.med.upenn.edu/hiv/assets/user-content/.../RABScoringv2.112.21.95.doc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment Form (GAF)</measure>
    <time_frame>baseline</time_frame>
    <description>Assessment of overall psychiatric function comprises Axis V in the DSM-IV (DSM-IV, 1994). GAF scores range from 0 to 100. A reasonably well-functioning person will score above 70; serious impairment is below 50.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amphetamine Drug Use</measure>
    <time_frame>baseline</time_frame>
    <description>Number of subjects who used Amphetamine in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cocaine Drug Use</measure>
    <time_frame>baseline</time_frame>
    <description>Number of subjects with cocaine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Marijuana Drug Use</measure>
    <time_frame>baseline</time_frame>
    <description>Number of subjects with Marijuana use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benzodiazepine Drug Use</measure>
    <time_frame>baseline</time_frame>
    <description>Number of subjects with benzodiazepine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">306</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Opioid-Related Disorders</condition>
  <arm_group>
    <arm_group_label>ONP + DNI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ON + DNIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONP + DNIP</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo naltrexone + placebo naltrexone implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naltrexone implant</intervention_name>
    <description>naltrexone implant is 1000 mg naltrexone</description>
    <arm_group_label>ONP + DNI</arm_group_label>
    <other_name>DNI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral naltrexone</intervention_name>
    <description>oral naltrexone 50 mg/day</description>
    <arm_group_label>ON + DNIP</arm_group_label>
    <other_name>ON</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral placebo naltrexone</intervention_name>
    <description>oral placebo naltrexone resembles active medication</description>
    <arm_group_label>ONP + DNI</arm_group_label>
    <arm_group_label>ONP + DNIP</arm_group_label>
    <other_name>ONP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo implant</intervention_name>
    <description>placebo implant resembles active medication</description>
    <arm_group_label>ON + DNIP</arm_group_label>
    <arm_group_label>ONP + DNIP</arm_group_label>
    <other_name>DNIP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current opioid dependence

          -  Recently completed opioid detoxification

        Exclusion Criteria:

          -  Serious medical or psychiatric condition requiring immediate hospitalization or that
             would make participation in the study hazardous

          -  Planning to leave the study area within the 12 months following study entry

          -  Imminent incarceration

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Woody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104 6178</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavlov Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>September 16, 2005</study_first_submitted>
  <study_first_submitted_qc>September 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <results_first_submitted>February 1, 2019</results_first_submitted>
  <results_first_submitted_qc>February 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 27, 2019</results_first_posted>
  <last_update_submitted>February 28, 2019</last_update_submitted>
  <last_update_submitted_qc>February 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects (SS) are from Leningrad Regional Alcoholism and Substance Abuse Treatment Center, Leningrad Region; and St. Petersburg City Alcoholism and Substance Abuse Treatment Center, screened for detoxification and if met study criteria and interested were referred to study on day of discharge. First SS admitted on 7/31/06, last visit was 1/4/09.</recruitment_details>
      <pre_assignment_details>SS were opioid dependent with physiological features for at least 1 year, negative urine for opioids, had ability to give informed consent, not on psychotropic medication, if female, not pregnant, could provide at least 1 relative contact, no significant lab abnormality, and not major psych disorder.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
          <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
        </group>
        <group group_id="P2">
          <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
          <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
        </group>
        <group group_id="P3">
          <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
          <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="102"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="86"/>
                <participants group_id="P3" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ONP + DNI</title>
          <description>Oral naltrexone placebo + Depot Naltrexone Implant 1000 mg
naltrexone implant: depot implant is 1000 mg naltrexone
placebo oral tablet: placebo oral tablet resembles active medication</description>
        </group>
        <group group_id="B2">
          <title>ON + DNIP</title>
          <description>Oral naltrexone 50 mg + Depot Naltrexone placebo Implant
oral naltrexone: oral naltrexone 50 mg/day
depot placebo implant: placebo implant resembles active medication</description>
        </group>
        <group group_id="B3">
          <title>ONP + DNIP</title>
          <description>Oral placebo naltrexone + placebo naltrexone implant
placebo oral tablet: placebo oral tablet resembles active medication
depot placebo implant: placebo implant resembles active medication</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="306"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B2" value="27.9" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B3" value="28.7" lower_limit="18" upper_limit="40"/>
                    <measurement group_id="B4" value="28.2" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="306"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="360"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retention Without Relapse to Heroin Addiction (Measured at Month 6)</title>
        <description>Survival analysis (Kaplan-Meier survival functions with log-rank Cox-Mantel criteria for group comparison was used to determine the primary outcome of retention, defined as not missing 2 consecutive counseling sessions and not having a relapse. Because this outcome combined patients who failed to keep appointments with those who kept appointments but relapsed, the proportion of non-survivors attributable to proven relapse.</description>
        <time_frame>6 months</time_frame>
        <population>Subjects who remained in treatment without relapse. remaining in treatment = 6 months manualized clinical counseling, plus medication.</population>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Retention Without Relapse to Heroin Addiction (Measured at Month 6)</title>
          <description>Survival analysis (Kaplan-Meier survival functions with log-rank Cox-Mantel criteria for group comparison was used to determine the primary outcome of retention, defined as not missing 2 consecutive counseling sessions and not having a relapse. Because this outcome combined patients who failed to keep appointments with those who kept appointments but relapsed, the proportion of non-survivors attributable to proven relapse.</description>
          <population>Subjects who remained in treatment without relapse. remaining in treatment = 6 months manualized clinical counseling, plus medication.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Dropped Out of Treatment</title>
        <description>Kaplan-Meier survival curves for the event of subjects who dropped out of treatment</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Dropped Out of Treatment</title>
          <description>Kaplan-Meier survival curves for the event of subjects who dropped out of treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive Opioid Urine Test</title>
        <description>missed urine tests were imputed to be positive for opiates</description>
        <time_frame>6 months</time_frame>
        <population>missing = positive; results negative for opioids</population>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Positive Opioid Urine Test</title>
          <description>missed urine tests were imputed to be positive for opiates</description>
          <population>missing = positive; results negative for opioids</population>
          <units>urine tests</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>urine tests</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>urine tests</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1428"/>
                <count group_id="O2" value="1428"/>
                <count group_id="O3" value="1428"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".427" lower_limit="0.40" upper_limit="0.45"/>
                    <measurement group_id="O2" value=".636" lower_limit="0.60" upper_limit="0.66"/>
                    <measurement group_id="O3" value=".341" lower_limit="0.32" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Alcohol</title>
        <description>use of alcohol grams per day</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Alcohol</title>
          <description>use of alcohol grams per day</description>
          <units>grams per day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.7"/>
                    <measurement group_id="O2" value="9.0" spread="1.7"/>
                    <measurement group_id="O3" value="9.6" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Score of Psychiatric Problems</title>
        <description>composite score is a decimal score; with 0 = no problems, 1 = the most problems based on the Addiction Severity Index composite score of 11 indexed questions.</description>
        <time_frame>6 months</time_frame>
        <population>mean of composite score</population>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Score of Psychiatric Problems</title>
          <description>composite score is a decimal score; with 0 = no problems, 1 = the most problems based on the Addiction Severity Index composite score of 11 indexed questions.</description>
          <population>mean of composite score</population>
          <units>composite score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.02"/>
                    <measurement group_id="O2" value="0.15" spread="0.02"/>
                    <measurement group_id="O3" value="0.18" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HIV Risk (Baseline)</title>
        <description>The Risk Assessment Behavior (RAB), is an HIV risk Scale. The Total Score is scored by adding the values that correspond to the responses selected by the subject for the items asked. This highest total score is 40 (highest risk), and the lowest score = 0 (no risk). This assessment has 2 Subsections: 1) Drug Risk = 8 questions (lowest Drug Risk score = 0 (no risk), and highest drug risk score = 22 =(greatest risk), 2) 10 Sex Risk questions: scores are 0 = no risk, and 18 = highest risk). Total RAB Score = Drug Risk Total + Sex Risk Total (0 = no risk, 40 = highest). See: Risk Assessment Battery (RAB) Scoring System, https://www.med.upenn.edu/hiv/assets/user-content/.../RABScoringv2.112.21.95.doc</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>HIV Risk (Baseline)</title>
          <description>The Risk Assessment Behavior (RAB), is an HIV risk Scale. The Total Score is scored by adding the values that correspond to the responses selected by the subject for the items asked. This highest total score is 40 (highest risk), and the lowest score = 0 (no risk). This assessment has 2 Subsections: 1) Drug Risk = 8 questions (lowest Drug Risk score = 0 (no risk), and highest drug risk score = 22 =(greatest risk), 2) 10 Sex Risk questions: scores are 0 = no risk, and 18 = highest risk). Total RAB Score = Drug Risk Total + Sex Risk Total (0 = no risk, 40 = highest). See: Risk Assessment Battery (RAB) Scoring System, https://www.med.upenn.edu/hiv/assets/user-content/.../RABScoringv2.112.21.95.doc</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="0.44"/>
                    <measurement group_id="O2" value="8.0" spread="0.47"/>
                    <measurement group_id="O3" value="8.7" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Global Assessment Form (GAF)</title>
        <description>Assessment of overall psychiatric function comprises Axis V in the DSM-IV (DSM-IV, 1994). GAF scores range from 0 to 100. A reasonably well-functioning person will score above 70; serious impairment is below 50.</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Global Assessment Form (GAF)</title>
          <description>Assessment of overall psychiatric function comprises Axis V in the DSM-IV (DSM-IV, 1994). GAF scores range from 0 to 100. A reasonably well-functioning person will score above 70; serious impairment is below 50.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.8" spread="0.7"/>
                    <measurement group_id="O2" value="64.7" spread="0.8"/>
                    <measurement group_id="O3" value="62.5" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amphetamine Drug Use</title>
        <description>Number of subjects who used Amphetamine in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Amphetamine Drug Use</title>
          <description>Number of subjects who used Amphetamine in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cocaine Drug Use</title>
        <description>Number of subjects with cocaine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ONP + DNI</title>
            <description>Oral naltrexone placebo (ONP) + Depot Naltrexone Implant (DNI) 1000 mg
naltrexone implant: naltrexone implant is 1000 mg naltrexone
oral placebo naltrexone: oral placebo naltrexone resembles active medication</description>
          </group>
          <group group_id="O2">
            <title>ON + DNIP</title>
            <description>Oral naltrexone (ON) 50 mg + Depot Naltrexone placebo Implant (DNIP)
oral naltrexone: oral naltrexone 50 mg/day
placebo implant: placebo implant resembles active medication</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP</title>
            <description>Oral placebo naltrexone + placebo naltrexone implant
oral placebo naltrexone: oral placebo naltrexone resembles active medication
placebo implant: placebo implant resembles active medication</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Drug Use</title>
          <description>Number of subjects with cocaine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Marijuana Drug Use</title>
        <description>Number of subjects with Marijuana use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Marijuana Drug Use</title>
          <description>Number of subjects with Marijuana use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Benzodiazepine Drug Use</title>
        <description>Number of subjects with benzodiazepine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
        <time_frame>baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
            <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
          </group>
          <group group_id="O2">
            <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
            <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
          </group>
          <group group_id="O3">
            <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
            <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
          </group>
        </group_list>
        <measure>
          <title>Benzodiazepine Drug Use</title>
          <description>Number of subjects with benzodiazepine drug use in the past 90 days at baseline as measured by the TimeLine Follow-back Form (TLFB) . The TLFB is an instrument that assesses substance use over a specified period of time (Sobel &amp; Sobel, 1992).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Years</time_frame>
      <desc>An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product. The event need not have a causal relationship to the treatment. Normal withdrawal is not considered an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>ON + DNIP, Oral Naltrexone + Depot Placebo Naltrexone Implant</title>
          <description>Oral naltrexone
Oral naltrexone: oral naltrexone 50 mg/day
DNIP
Depot Placebo Naltrexone Implant</description>
        </group>
        <group group_id="E2">
          <title>DNI + ONP , Naltrexone Implant + Oral Naltrexone Placebo</title>
          <description>naltrexone implant
naltrexone implant: The implant is 1000 mg naltrexone
ONP oral naltrexone placebo tablet</description>
        </group>
        <group group_id="E3">
          <title>ONP + DNIP, Oral Placebo Naltrexone and Depot Placebo Implant</title>
          <description>ONP daily placebo oral naltrexone
monthly placebo depot naltrexone implant</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>cholecystectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="102"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="102"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>high blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="102"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>increased liver enzyme</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>drowsiness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>local site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="102"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="102"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitations include limited amount of data on patients who did not remain in treatment, thus making it difficult to obtain more accurate information on the proportions with relapse at 9- and 12- month follow-ups and other secondary outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. George E Woody</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-746-7702</phone>
      <email>woodg@pennmedicine.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

